On April 25, 2025 Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, reported the publication of 3 abstracts for poster presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2025 (Press release, Obsidian Therapeutics, APR 25, 2025, View Source [SID1234652179]). In addition to a trial-in-progress study design update on the ongoing multicenter study Agni-01 (NCT06060613), Obsidian will share preclinical data from our cytoDRiVE platform demonstrating spatiotemporal regulation of membrane-bound IL12 in syngeneic solid tumor models and preclinical data on OBX-115 TIL phenotype starting from NSCLC tumor tissue.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Obsidian is presenting new preclinical data from its cytoDRiVE regulation platform, further demonstrating the ability to unlock the therapeutic window of potent cytokines and broaden the reach of armored cell therapies. The poster for abstract LB025 demonstrates the application of Obsidian’s regulatable cytoDRiVE platform to enhance antigen-responsive ("spatial") promoter-induced activation by adding a critical pharmacologically regulatable ("temporal") signal to exert tight "spatiotemporal" control over IL12 expression1, resulting in a positive impact on safety and tumor control in syngeneic solid tumor models.

Obsidian will also present preclinical data from a multimodal phenotyping analysis comparing OBX-115 TIL generated with its proprietary manufacturing process to conventional, non-engineered TIL using NSCLC tumor samples. The poster for abstract LB359 provides evidence that, as observed with melanoma2, the OBX-115 process generates a minimally exhausted, CD8+ enriched and memory "stem-like" T-cell phenotype. Additionally, the tumor reactive gene signature analysis showed that the drug product is enriched for putative tumor-reactive T-cell clonotypes.

Obsidian Posters at AACR (Free AACR Whitepaper) 2025:

Spatiotemporally regulated expression of membrane-bound interleukin 12 (mbIL12) for armored adoptive cell therapy (ACT) shows strong antitumor activity in syngeneic solid tumor models without overt toxicity (Abstract LB025)
Presenting Author: Ross T, Obsidian Therapeutics
Poster: Sunday, April 27, 2:00-5:00pm CT
OBX -115 TIL from non-small cell lung cancer (NSCLC) are enriched for putative tumor-reactive, stem-like T cells with enhanced tumor cytotoxicity: Results from multimodal phenotyping analysis (Abstract LB359)
Presenting Authors: Schoenfeld AJ, Memorial Sloan Kettering Cancer Center
Poster: Tuesday, April 29, 2:00-5:00pm CT
Trial in progress: Phase 1/2 study of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced solid tumors (Abstract CT244)
Presenting Author: Shoushtari AN, Memorial Sloan Kettering Cancer Center
Poster: Tuesday, April 29, 2:00-5:00pm CT
1 Smith et al., SITC (Free SITC Whitepaper) 2024 (Abstract 463).
2 Bernatchez et al., ISCT 2024 (Abstract 909).

About OBX-115

Obsidian’s lead investigational cytoTIL15 program, OBX-115, is a novel engineered tumor-derived autologous T cell immunotherapy (tumor-infiltrating lymphocyte [TIL] cell therapy) armored with pharmacologically regulatable membrane-bound IL15 (mbIL15). OBX-115 has the potential to become a meaningful therapeutic option for patients with advanced or metastatic melanoma and other solid tumors by leveraging the expected benefits of mbIL15 and Obsidian’s proprietary, differentiated manufacturing process to enhance persistence, antitumor activity, and clinical safety of TIL cell therapy. Obsidian is investigating OBX-115 in the phase 1/2 Agni-01 multicenter trial in patients with advanced solid tumors (NCT06060613).

On April 25, 2025 InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company, reported that its BTK inhibitor orelabrutinib received approval from the China National Medical Products Administration (NMPA) for the first-line treatment of patients with chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) (Press release, InnoCare Pharma, APR 25, 2025, View Source [SID1234652178]). The approval of the first-line CLL/SLL treatment will enable orelabrutinib to benefit an even broader population of lymphoma patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Orelabrutinib has been approved for the treatment of three indications in China, including relapsed and refractory (R/R) CLL/SLL, r/r mantle cell lymphoma (R/R MCL) and r/r marginal zone lymphoma (R/R MZL), all of which have been covered in the National Reimbursement Drug List.

Jianyong Li, the principal investigator of the clinical trial and a professor at the Jiangsu Province Hospital, said: "Orelabrutinib has demonstrated excellent efficacy and safety in the treatment of B-cell malignancies such as R/R CLL/SLL since its launch in 2020, showing a higher complete response rate. The first-line approval means more lymphoma patients will benefit from this highly effective treatment regimen. The study showed a complete response rate as high as 12.1%, which will bring new hope to the treatment of hematological tumors in China."

Lugui Qiu, the principal investigator of the clinical trial and a professor at the Blood Diseases Hospital of the Chinese Academy of Medical Sciences and Peking Union Medical College, said, "Despite the challenges posed by the COVID-19 pandemic in initiating the study, enrolling patients and patient management, orelabrutinib demonstrated significant efficacy and good safety in first-line treatment of CLL/SLL. It also provides an effective treatment option for high-risk patients and those with comorbidities, both in clinical research and real-world settings."

Jun Ma, professor at the Harbin Blood Disease and Oncology Research Institute, said, "With the approval of orelabrutinib for first-line CLL/SLL treatment and the accumulation of additional real-world data, more lymphoma patients will benefit. Furthermore, orelabrutinib has been listed as a Class I recommendation for first-line treatment of CLL/SLL in the CSCO lymphoma guidelines. We look forward to more extensive and longer follow-up data on orelabrutinib to guide clinical practice and offer better treatment options for more lymphoma patients."

Jun Zhu, professor at Beijing Cancer Hospital said, "The prospect of orelabrutinib in the treatment of hematological tumors is remarkable. Its high selectivity and low off-target effects give it advantages in both efficacy and safety. We believe that with the extensive use of orelabrutinib in first-line treatment, more patients will benefit from this novel therapy."

Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, said: "We are delighted to see the approval of orelabrutinib for the first-line treatment of CLL/SLL. This marks another important milestone for our company in hematological malignancies. We sincerely thank all the physicians, patients and employees who have worked tirelessly on this study. We look forward to bringing new hope and treatment options to more lymphoma patients."

Orelabrutinib is a novel BTK inhibitor developed by InnoCare. With high target selectivity, it can avoid adverse events related to off-target effects and improve safety and efficacy.

CLL/SLL, one of the most prevalent forms of leukemia, is an indolent malignancy of B lymphocytes. Globally, there are 191,000 newly diagnosed CLL cases each year, with 61,000 related deaths1. The incidence rate of CLL/SLL is on the rise in China.

On April 25, 2025 Incyte (Nasdaq:INCY) reported that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2025 in Chicago, IL, from April 25–30 (Press release, Incyte, APR 25, 2025, View Source [SID1234652177]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"At AACR (Free AACR Whitepaper) we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors," said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. "These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms."

Abstracts accepted for presentation at AACR (Free AACR Whitepaper) include:

Mini Symposium

INCB177054

INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity
(Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #3789.))

Poster Presentations

INCA33890

INCA33890 Increases CD8+ T-Cell Effector Function Compared with pembrolizumab as Assessed by Single-Cell RNA Sequencing in Human PD-1xTGFβR2 Knock-In Mouse Model (Session Title: Immune Fitness and Metabolic Regulation of Cancer Immunity​. April 29, 10:00 a.m. – 1:00 p.m. ET (9:00 a.m. – 12:00 p.m. CT). Abstract #4861.))

INCA33890, a Bispecific Antibody Targeting PD-1 and TGFβR2, Shows Enhanced Immune Responses in Models of Ovarian Cancer
(Session Title: Antibodies 3: Multi-Target Checkpoint Inhibitors and Immune Activators. April 29, 3:00 p.m. – 6:00 p.m. ET (2:00 – 5:00 p.m. CT). Abstract #6074.))

PD-1xTGFβR2 Bispecific Biclonics Antibody INCA33890 Augments Human T-Cell Effector Functions In Vitro and Ex Vivo
(Session Title: Antibodies 3: Multi-Target Checkpoint Inhibitors and Immune Activators​. April 29, 3:00 p.m. – 6:00 p.m. ET (2:00 – 5:00 p.m. CT). Abstract #6071.))

INCB057643

INCB057643, a Bromodomain and Extra-Terminal (BET) Protein Inhibitor, Improved Bone Marrow Function and Shifted Megakaryopoiesis to Erythropoiesis in Patients with Myeloproliferative Neoplasms (MPNs)
(Session Title: Molecular Genetics and Epigenetics of Tumors​. April 30, 10:00 a.m. – 1:00 p.m. ET (9:00 a.m. – 12:00 p.m. CT). Abstract #7188.))

Novel Role of INCB057643, a Bromodomain and Extra-Terminal (BET) Protein Inhibitor, in Myeloid Cell Regulation and Immunosuppressive Tumor Environment Remodeling in Myelofibrosis (MF)
(Session Title: Molecular Genetics and Epigenetics of Tumors​. April 30, 10:00 a.m. – 1:00 p.m. ET (9:00 a.m. – 12:00 p.m. CT). Abstract #7184.))

Association of Cyclin E1 Expression with Genomic Instability in Ovarian Cancer
(Session Title: Origins and Mechanisms of Genomic Instability​. April 28, 3:00 p.m. – 6:00 p.m. ET (2:00 – 5:00 p.m. CT). Abstract #2846.))

On April 25, 2025 Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, reported that 18 abstracts, including one oral presentation, have been accepted for presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2025, on April 25 – 30 in Chicago (Press release, Tempus, APR 25, 2025, View Source [SID1234652176]). Tempus researchers will showcase scientific and clinical research that highlight the transformative impact of AI on oncology treatment and patient outcomes.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Tempus is proud to showcase a comprehensive collection of scientific research this year, highlighting the impact of our multimodal dataset and AI-enabled diagnostic solutions on cancer research," said Kate Sasser, PhD, Chief Scientific Officer at Tempus. "AACR stands as a leading forum for cancer research, and we look forward to presenting our findings alongside our collaborators in Tempus’ home city of Chicago."

Research highlights include:

Oral Presentation: Investigating the clinical landscape and biological impact of SF3B1 hotspot mutations in breast cancer
Date/Time: April 27, 2025; 4:40 PM – 4:45 PM CT
Location: To be announced

Overview: This study examines the implications of SF3B1 hotspot mutations in breast cancer, focusing on genetic profile, survival outcomes, and biological impacts, by analyzing de-identified data from Tempus’ multimodal real-world database consisting of 420 breast cancer patients with SF3B1 mutations. Innovative genome editing in isogenic breast cell lines revealed that SF3B1 mutations negatively impact cell growth and tumor development. The findings support the utility of SF3B1 mutations as potential therapeutic targets and underscore the importance of understanding their role in cancer biology, with ongoing research aimed at uncovering the mechanisms behind hotspot-specific effects.
Poster Presentation: Genetic and clinical landscape of NUTM1 structural variants
Date/Time: April 28, 2025; 2:00 PM – 5:00 PM CT
Location: Section 34
Overview: Within Tempus’ multimodal real-world database, researchers identified 59 patients with a primary diagnosis of NUT carcinoma—an aggressive cancer—81% of whom had a confirmed NUTM1 fusion. Notably, there were 106 additional patients who had a NUTM1 fusion without a corresponding initial NUT carcinoma diagnosis, suggesting a potentially significant underdiagnosis rate. The study found a variety of fusion gene partners, with certain cancer types showing enrichment of specific fusions. With a median overall survival of just over 5 months, the findings suggest that certain cancer types with a high enrichment of NUTM1 fusions may benefit from universal next-generation sequencing to ensure accurate diagnosis and potentially improve outcomes for patients with high-risk cancer types.
Poster Presentation: A longitudinal, circulating tumor molecular response biomarker as a predictor of clinical outcomes in a real-world cohort of patients with advanced solid tumors treated with tyrosine kinase inhibitors
Date/Time: April 29, 2025; 9:00 AM – 12:00 PM CT

Location: Section 45

Overview: In a study analyzing advanced cancer patients, researchers evaluated the prognostic value of changes in circulating tumor DNA tumor fraction (ctDNA TF) during tyrosine kinase inhibitor (TKi) therapy. The study, which consisted of 109 patients from Tempus’ multimodal real-world database, found that molecular responders had significantly longer real-world overall survival (rwOS) than molecular non-responders across various cancer types. The findings suggest that ctDNA TF may serve as a biomarker to predict molecular response to TKi therapy, potentially guiding treatment decisions and improving patient outcomes in a real-world setting.
Collaborator-led Poster Presentation: Enhancing TCR-T with a Fas-based switch receptor boosts T cell engraftment, persistence, and anti-tumor activity in models of hard-to-treat PRAME solid tumor indications
Date/Time: April 29, 2025; 9:00 AM – 12:00 PM CT

Location: Section 39

Overview: T-knife Therapeutics is developing a FAS-based switch receptor (FAS-TNFR) to target PRAME-positive solid tumors, designed to enhance T cell activity and overcome the hostile tumor microenvironment. Utilizing Tempus multi-modal data, T-Knife analyzed a large database of tumor samples to identify the inhibitory ligands most frequently found in PRAME-expressing indications and to understand in depth the pattern of expression of PRAME and inhibitory ligands in different patient populations. These insights provided by Tempus were crucial for T-knife to select the optimal switch receptor from their armoring toolbox and determine appropriate target populations for their upcoming clinical trials (Figures 1A, 2D, and 3A-C present Tempus-driven data and insights).

On April 25, 2025 TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), reported its financial results for the fiscal year ending December 31, 2024, and provides a business update (Press release, TME Pharma, APR 25, 2025, View Source [SID1234652175]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Annual Report 2024, as approved by the management and supervisory boards on April 24, 2025, is available on TME Pharma’s website (www.tmepharma.com).

"TME Pharma achieved a number of significant clinical and regulatory milestones in 2024 and, as 2025 progresses, we remain committed to advancing the key initiatives that make up our strategic roadmap," said Aram Mangasarian, CEO of TME Pharma. "While strategic partnerships cannot be precisely timed, some of our discussions with potential partners and investors regarding strategic transactions for both NOX-A12 and NOX-E36 have been constructive. The regulatory validation of NOX‑A12’s Phase 2 randomized, controlled study design in glioblastoma by authorities in the US and Germany represented a key step in defining the clinical development pathway. Additionally, we have made important progress on getting NOX-E36 ready for clinical development in ophthalmic indications supported by promising preclinical data. While we pursue these clinical and strategic goals, we are also proactively preparing for contingencies to ensure operational continuity. Should strategic transactions not materialize by mid-2025, we will be ready to transition to a fully virtual and outsourced organizational structure, which would allow us to minimize costs while continuing to engage with industrial partners and investors to advance our clinical programs. By leveraging this flexible setup, we aim to preserve value for our shareholders."

Business and Clinical Highlights for 2024 and 2025 Year-to-Date

Brain Cancer (Glioblastoma) – Unprecedented Clinical Benefit

Glioblastoma is a highly aggressive and deadly form of brain cancer in which TME Pharma’s lead asset NOX-A12 has generated unprecedented clinical benefit in the GLORIA Phase 1/2 study. Newly diagnosed patients with glioblastoma tumors resistant to standard of care chemotherapy (MGMT unmethylated) and that are not amenable to complete surgical removal face a devastating prognosis of median overall survival (mOS) of approx. 10 months on standard of care. The development of effective treatments for these patients – TME Pharma’s target population in the GLORIA trial – is particularly challenging since these tumors tend to be more aggressive and less responsive to current therapies. Despite these unfavorable factors for the patients, TME Pharma’s development program of its lead asset, the CXCL12 inhibitor NOX-A12, suggests a strong signal of clinical benefit in this patient population.

In early March 2024, the Food and Drug Administration (FDA) cleared TME Pharma’s Investigational New Drug (IND) application on the basis of the protocol for its upcoming randomized Phase 2 trial in glioblastoma. Furthermore, in early April 2024, the company announced that the US FDA had granted Fast Track Designation for NOX-A12, in combination with radiotherapy and bevacizumab for newly diagnosed glioblastoma patients with chemotherapy-resistant disease and measurable tumor remaining after surgery.

Near-final efficacy data on glioblastoma patients treated with NOX-A12 combined with anti-VEGF and radiotherapy were presented by the lead investigator of the clinical trial, Dr. Frank Giordano, at a high-profile international cancer conference – the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress in September 2024 – revealing statistically significant improvement in survival for this triple combination over a standard of care reference cohort as well as NOX-A12 + radiotherapy alone (without anti-VEGF). The final median overall survival of the GLORIA 1/2 trial of the arm combining NOX-A12 with radiotherapy and bevacizumab achieved a remarkable 19.9 months. This exceeds what the company believes to be all relevant competitor studies conducted in the US or EU involving newly diagnosed, chemotherapy-resistant (MGMT unmethylated) glioblastoma patients.

Promising New Opportunities for NOX-E36 in Ophthalmology

TME Pharma’s second clinical stage asset, the CCL2 inhibitor NOX-E36, previously completed four clinical trials and has already been administered to 175 human subjects. While in an oncology setting NOX-E36 targets the tumor microenvironment by modifying the innate immune system, it has also demonstrated significant potential in addressing unmet medical need in ophthalmic diseases affected by scarring (fibrosis) and inflammation.

The anti-fibrotic mode of action of NOX-E36 has already been demonstrated in a relevant animal model, and the company believes that development in ophthalmological indications could be a promising opportunity to diversify its project portfolio. The company is pursuing resource-efficient possibilities to perform clinical studies such as investigator-initiated trials (IIT) funded and performed by research institutes, with TME Pharma supplying the drug. In parallel, TME Pharma is discussing with potential partners and venture capital firms the best way to develop NOX-E36 in the ophthalmology space with minimal or no financial contribution from TME Pharma’s shareholders.

TME Pharma has been collaborating with the Singapore Eye Research Institute (SERI) for several years and recent data from preclinical studies by SERI was selected for poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in May 2025. The preclinical data show that mNOX-E36 offers a more favorable safety profile than standard of care mitomycin C (MMC), while demonstrating comparable efficacy in reducing post-operative inflammation and scarring (fibrosis) following glaucoma filtration surgery, a common procedure to reduce intraocular pressure. Unlike MMC, mNOX-E36 does not destroy blood vessels in the conjunctiva, potentially overcoming the substantial toxicity seen with MMC, which is a key limitation of this current standard treatment. Fibrosis and inflammation are also significant causes of treatment failure in back-of-the-eye indications, such as age-related macular degeneration and proliferative diabetic retinopathy. TME Pharma believes that anti-CCL2 therapy with NOX-E36 offers a novel therapeutic approach to address these issues and potential to access larger markets.

Due to these new findings and other unpublished data, TME Pharma and SERI have filed patent applications covering use of NOX-E36 in glaucoma filtration surgery and other ophthalmic diseases to support its development through a license to an industrial partner or the creation of a new corporate entity.

Post-Period Event – AI-Driven Drug Discovery

In January 2025, TME Pharma announced a partnership with aimed analytics, a cutting-edge data analytics company, to enhance TME Pharma’s capabilities to leverage artificial intelligence (AI) in drug discovery and optimization. The goal of the collaboration is to use AI to create new and improved drug candidates with accelerated timelines and without the need for resource-intensive laboratory testing. The collaboration should also strengthen TME Pharma’s corporate profile for strategic transactions and reinforce ongoing partnering discussions.

2024 Financial Summary

TME Pharma successfully strengthened its balance sheet by raising €7.6 million (gross) in 2024. Considering cash and cash equivalents of €3.2 million as of December 31, 2024, TME Pharma has financial visibility into June 2025.

As in prior years, TME Pharma has not generated any revenues. The Group – TME Pharma N.V., TME Pharma AG and TME Pharma Inc. – does not expect to generate any revenues from any product candidates that it develops until the Group either signs a licensing agreement or obtains regulatory approval and commercializes its products or enters into collaborative agreements with third parties and relies on dilutive and non-dilutive financing until it reaches profitability.

Research and development (R&D) expenses decreased 13% from K€ 2,652 in the fiscal year (FY) 2023 to K€ 2,296 in the FY 2024. The decrease in research and development expenses in 2024 compared to 2023 is primarily due to the clinical trial of NOX-A12 in brain cancer nearing completion, which required lower costs while at the same time generating more mature data. The pancreatic cancer clinical trial phase 2 protocol which has been approved by the FDA in the US has not been initiated, thereby keeping ongoing costs related to this clinical trial minimal. As a result, TME Pharma was able to decrease drug manufacturing costs, service fees and other costs related to the clinical trials and preclinical testing, in addition to lower personnel expenses, patent costs and consulting services, partly offset by higher other research and administrative expenses.

General and administrative (G&A) expenses decreased from K€ 2,989 in the FY 2023 to K€ 2,981 in the FY 2024. The decrease in G&A expenses in 2024 compared to 2023 is mainly driven by lower personnel expenses as well as lower public and investor relations expenses and other expenses, partly offset by higher legal, consulting and audit fees in connection with the financing transactions in 2024. Other general and administrative expenses comprise mainly of depreciation of rights of use assets and equipment, supervisory board remuneration, insurance premium, and ancillary leasing costs.

The finance income in the FY 2024 and 2023 was non-cash finance income. Finance income decreased from K€ 399 in the FY 2023 to K€ 32 in the FY 2024 as a result of ending the Atlas convertible bonds financing facility with Atlas Special Opportunities LLC (ASO). Finance income in 2024 mainly resulted from fair value adjustments of detachable warrants (ABSA Warrants) issued in connection with the preferential rights issue. In 2023, finance income of K€ 237 resulted from the derecognition of conversion rights in connection with the ASO financing upon conversion and redemption of the bonds and of K€ 162 fair value adjustments of ABSA Warrants issued in connection with the preferential rights issue.

Finance cost decreased from K€ 1,518 in the FY 2023 to K€ 503 in the FY 2024 as a result of ending the Atlas convertible bonds financing facility with ASO. Finance cost in the FY 2024 and 2023 was non-cash finance cost, except for transaction costs of K€ 16 in 2024 and K€ 4 in 2023 borne by the company in conjunction with the exercise of ABSA Warrants (in 2024) and the issuance of Atlas convertible bonds (in 2023) as well as K€ 2 in 2024 and K€ 13 in 2023 relating to interest expense for lease liabilities. Finance cost in the FY 2024 of K€ 489 relate to the initial recognition of ABSA Warrants amounting to K€ 113 as well as losses of K€ 376 from exercises of such warrants. Finance cost in the FY 2023 of K€ 1,505 relate to the ASO facility (contractually entered into in 2020 and ended in 2023, except for outstanding convertible bonds that were fully redeemed in cash in the FY 2024) and comprise losses on initial recognition of convertible bonds, conversion losses, conversion right derivatives, interest in exchange for the lock-up of convertible bonds issued and outstanding as well as transaction costs.

As a result of these factors, TME Pharma N.V. reports a net loss for FY 2024 of K€ 5,722 compared to K€ 6,736 in the FY 2023, a decrease of 15%.

Outlook for 2025

TME Pharma’s strategic focus for 2025 centers on maximizing the value of its clinical-stage assets, NOX‑A12 and NOX-E36, through strategic partnerships, licensing agreements, and potential M&A. The company is pursuing these opportunities while maintaining a lean cost structure and actively preparing for a contingency plan involving a fully outsourced organizational structure, should targeted financing or strategic transactions not materialize by June 2025.

NOX-A12 in Glioblastoma

Given the unprecedented clinical data and clear regulatory pathway, TME Pharma has strategically prioritized the development of NOX-A12 in first-line, chemotherapy resistant glioblastoma since the company believes this indication offers the fastest path to regulatory approval for NOX-A12 in the solid tumor space.

The partnering package for NOX-A12 in glioblastoma is particularly attractive due to:

Significant Clinical Benefit: Statistically significant improvement in survival for NOX-A12 with radiotherapy and anti-VEGF bevacizumab compared to both the standard of care reference cohort (p=0.003) and the cohort treated with NOX-A12 and radiotherapy alone (p=0.021).
Regulatory Validation: A clear regulatory pathway with a Phase 2 design approved by the US FDA and the German BfArM and enhanced regulatory interactions with Fast-Track status granted by the FDA in the US and Orphan Drug Designations granted in the US and EU.
Commercial Protection: Commercial protection provided by the Orphan Drug Designations and potentially also by the patent application filed in 2022 covering the NOX-A12, radiotherapy and bevacizumab combination, which would provide cover into the 2040s if granted.
Non-dilutive Funding: Non-dilutive financial support of more than €7 million pledged for the approved Phase 2 trial once it is initiated, including a €2.4 million grant from the German federal government.
Trial Readiness: Clinical trial grade (GMP) NOX-A12 sufficient to rapidly initiate the approved Phase 2 trial at the six centers already open in Germany.
NOX-E36 in Ophthalmology

TME Pharma recognizing NOX-E36 potential in ophthalmology has chosen to collaborate with the Singapore Eye Research Institute (SERI) to maximize efficiency and minimize required resources for further development of the asset.

The NOX-E36 program is poised for rapid advancement into the clinic on the basis of:

Strong Scientific Rationale: Compelling preclinical proof-of-concept and clinical data supporting CCL2 as a valid target.
Funding Opportunities: Funding for Phase 1b study potentially available through grants accessible to SERI
IP Protection: Joint patent applications filed for the use of NOX-E36 in eye diseases in March 2025.
Drug Availability: GMP drug supply manufactured and ready to use pending local ocular toxicity bridging for subconjunctival administration, ensuring a smooth transition to clinic.
Established Safety Profile: Excellent systemic safety and tolerability and dose-dependent pharmacologic activity established in 175 human subjects across previous clinical trials.
As part of its most recent business planning TME Pharma is pursuing several transaction structures in parallel for its drug candidates:

Out-licensing NOX-A12: Seeking an exclusive worldwide or regional out-licensing deal for NOX-A12 program to a pharmaceutical partner. The targeted transaction structure would bring in payments upon signature and significant regulatory and commercial milestones as well as providing for royalties on sales.
Out-licensing NOX-E36: Seeking an exclusive worldwide out-licensing deal for NOX-E36 program both by TME Pharma and collaboration partner SERI to a newly formed company funded by venture capital partners.
Asset Sale: Exploring the sale of the private operational subsidiary TME Pharma AG holding assets and intellectual property to a pharmaceutical partner or investor. This would result in TME Pharma N.V. holding either cash or shares of the acquiring entity.
Virtual Setup: As a contingency plan in case none of the above can be realized by June 2025, TME Pharma is preparing to change its organizational structure to allow it to continue pursuing the goals of financing, licensing or M&A transactions focused on its clinical stage assets, NOX‑A12 and NOX-E36 while minimizing costs by outsourcing essentially all functions to maintain and advance the programs and conduct industrial partner and investor outreach.
The outsourced staffing structure will likely be the most economically efficient option to manage collaborations and develop further transactions on NOX-A12 and NOX-E36 and so TME Pharma is actively preparing to transition to a fully outsourced staffing structure at the end of June 2025.